June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
IL-2/IL-2 Ab complex plus rapamycin ameliorate experimental autoimmune uveoretinitis associated with expansion of CD4+Foxp3+ regulatory T cells
Author Affiliations & Notes
  • Hiroshi Keino
    Ophthalmology, Kyorin University, Mitaka, Japan
  • Yasuhiko Sato
    Ophthalmology, Kyorin University, Mitaka, Japan
  • Annabelle Okada
    Ophthalmology, Kyorin University, Mitaka, Japan
  • Footnotes
    Commercial Relationships Hiroshi Keino, None; Yasuhiko Sato, None; Annabelle Okada, Mitsubishi Tanabe Pharma (F), Novartis Pharma Japan (F), Novartis Pharmaceuticals Corporation (C), Xoma (C), Santen Pharmaceutical Corporation (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2024. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Hiroshi Keino, Yasuhiko Sato, Annabelle Okada; IL-2/IL-2 Ab complex plus rapamycin ameliorate experimental autoimmune uveoretinitis associated with expansion of CD4+Foxp3+ regulatory T cells. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2024.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To determine whether injection of IL-2/IL-2Ab together with rapamycin is effective in reducing ocular inflammation in experimental autoimmune uveoretinitis (EAU).

Methods: C57BL/6J mice were immunized with human interphotoreceptor retinoid binding protein peptide (h-IRBP1-20). Mice were injected i.p. with PBS, IL-2/IL-2Ab (JES6-1), rapamycin, or IL-2/IL-2Ab plus rapamycin on days 1, 2, 3, and 4 after immunization. Fundus examination was performed on days 9, 12, 15, 18, and 21 after immunization. The expression of Foxp3 on CD4+ T cells from draining lymph nodes (LNs) was examined by flow cytometry on day 7.

Results: Injection of IL-2/IL-2Ab plus rapamycin significantly reduced the clinical score of EAU on days 12, 15 and 18 compared to PBS, IL-2/IL-2Ab, or rapamycin treated mice. In addition, mice treated with IL-2/IL-2Ab plus rapamycin showed decreased severity of EAU by histopathological analysis. Although the expansion of CD4+Foxp3+ regulatory T cells (Tregs) was observed on day 7 in draining LNs from IL-2/IL-2Ab, rapamycin, and IL-2/IL-2Ab plus rapamycin treated mice, the expansion of Tregs was most prominent in IL-2/IL-2Ab plus rapamycin treated mice.

Conclusions: These results indicate that injection of IL-2/IL-2Ab plus rapamycin is effective in reducing ocular inflammation in EAU and in inducing the expansion of CD4+Foxp3+ Tregs. In vivo expansion of T regs using IL-2/IL-2Ab plus rapamycin may have clinical potential for the treatment of human refractory uveitis.

Keywords: 555 immunomodulation/immunoregulation  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×